- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT06828185
Randomisert enkeltblindet studie av pasient rapporterte erfaringer med sparing av ekstern skrå fascia vs standard inguinal orkiektomi (PRESERVE)
The purpose of this study is to evaluate the difference in patient-reported postoperative outcomes between two standard-of-care surgical techniques for radical orchiectomy (inguinal orchiectomy versus external oblique fascia sparing orchiectomy) for treatment of patients with suspected testicular malignancy. The main questions it aims to answer are:
- Does sparing the external oblique fascia during orchiectomy reduce pain after surgery?
- Is there a difference in narcotic consumption after surgery?
- Is there a difference in neuropathic pain after surgery?
- Is there a difference in complications after surgery?
Studieoversikt
Status
Forhold
Detaljert beskrivelse
Radical inguinal orchiectomy is the standard of care surgical approach for removing a testicle when clinically there is concern for testicular cancer. The procedure is generally minor and performed in the outpatient setting. Recent data demonstrates a trend towards high opioid prescription following this procedure in an attempt to minimize postoperative pain, which is associated with persistent new opioid use in the future. Numerous efforts have been put in place to minimize postoperative pain following scrotal procedures, with success noted when opioid sparing pathways have been adopted. However, there has been sparse data on modifications within surgical technique that could improve patient pain following this procedure.
There have been various descriptions of technique to performing a radical orchiectomy which involves removal of the diseased testicle and spermatic cord. Classically, performing a radical inguinal orchiectomy involves incision of the external oblique fascia to expose and ligate the spermatic cord. During this step, the ilioinguinal nerve is exposed and can be injured by either traction injury or inadvertent transection. Modifications to this technique have been described which involve sparing of the external oblique fascia. Both approaches are performed via a similar incision and both the testicle and spermatic cord are removed. In fascia sparing modification, the spermatic cord is controlled, dissected, and subsequently ligated at the level of the superficial inguinal ring without incising the external oblique fascia. Proponents of this approach suggest the potential for less convalescence and faster recovery due to less tissue manipulation and avoidance of disturbances to the ilioinguinal nerve. Despite this potential benefit, there is no evidence to demonstrate superiority of either approach as it relates to patient recovery.
Therefore, we propose a randomized single-blinded clinical trial investigating postoperative pain outcomes of inguinal radical orchiectomy compared to external oblique fascia sparing radical orchiectomy.
Studietype
Registrering (Antatt)
Fase
- Ikke aktuelt
Kontakter og plasseringer
Studiekontakt
- Navn: Muhannad Alsyouf, MD
- Telefonnummer: 44196 9095584000
- E-post: Malsyouf@llu.edu
Studer Kontakt Backup
- Navn: Brian Hu, MD
- Telefonnummer: 44196 9095584000
- E-post: Bhu@llu.edu
Studiesteder
-
-
California
-
Loma Linda, California, Forente stater, 92354
- Rekruttering
- Loma Linda University
-
Ta kontakt med:
- Muhannad Alsyouf, MD
- Telefonnummer: 44196 9095584000
- E-post: Malsyouf@llu.edu
-
Hovedetterforsker:
- Muhannad Alsyouf, MD
-
Los Angeles, California, Forente stater, 90089
- Rekruttering
- University of Southern California
-
Hovedetterforsker:
- Siamak Daneshmand
-
Ta kontakt med:
- Siamak Daneshmand, MD
- Telefonnummer: 3238653589
- E-post: daneshma@med.usc.edu
-
Underetterforsker:
- Hooman Djaladat
-
Underetterforsker:
- Anne Schuckman
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Participants undergoing radical orchiectomy for suspected testicular malignancy
- Testicular malignancy can be germ cell tumor or non germ cell tumors, including paratesticular tumors as long as a radical orchiectomy is planned
- Participants over 18 years of age who can provide informed consent
- Participants not currently using opiates for another reason
- Regional and metastatic patients are allowed, as long as participant does not require opiates for pain related to metastatic disease
- No contraindication for participant to receive standardized medication pathway in the peri-operative period.
Exclusion Criteria:
- Clinical T4 disease
- History of illicit substance abuse (including prior opioid abuse) except for marijuana
- Participants who underwent chemotherapy or radiotherapy prior to orchiectomy
- Opioid use within 1 month of study enrollment
- Participants with large testis masses requiring skin incision larger than 8 cm in size.
- Participants with large testis masses requiring orchiectomy through an incision other than the standard transverse inguinal incision (i.e. hockey stick incision, vertical incision)
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Annen
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Enkelt
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Aktiv komparator: Radikal inguinal orkiektomi
|
External oblique fascia will be incised during orchiectomy |
|
Aktiv komparator: Radikal ytre skrå fascia sparende orkieektomi
|
External oblique fascia will be spared during orchiectomy |
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Postoperative Pain Level
Tidsramme: Change between Postoperative day 0 [the day surgery was completed] through postoperative day 7
|
Post-operative pain levels will be measured by the Short Form Inguinal Pain Score (sf-IPQ) The score range is between 0 and 12, with zero points indicating no pain and 12 points indicating the most intense pain. Scores for subjects undergoing inguinal orchiectomy will be compared to subjects undergoing external oblique fascia sparing radical orchiectomy. |
Change between Postoperative day 0 [the day surgery was completed] through postoperative day 7
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Opioid consumption
Tidsramme: Change between Postoperative day 0 [the day surgery was completed] through postoperative day 7
|
Subjects will self-report the total number of Oxycodone 5 mg tablets consumed for breakthrough pain during the first post-op week. There is no pre-defined range for this self-report but the higher the number of tablets consumed may be an indication of great pain intensity. |
Change between Postoperative day 0 [the day surgery was completed] through postoperative day 7
|
|
Neuropathic Pain Level
Tidsramme: Change between Postoperative day 0 [the day surgery was completed] through postoperative day 7)
|
Post-Operative Neuropathic pain levels will be measured by the modified Barrow Neurological Institute hypesthesia scale. A total score ranging between 1 and 4, with 1 representing minimal neuropathic pain and 4 representing intense neuropathic pain. |
Change between Postoperative day 0 [the day surgery was completed] through postoperative day 7)
|
Samarbeidspartnere og etterforskere
Sponsor
Samarbeidspartnere
Publikasjoner og nyttige lenker
Studierekorddatoer
Studer hoveddatoer
Studiestart (Antatt)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
- Urogenitale sykdommer
- Kjønnssykdommer
- Smerte
- Nevrologiske manifestasjoner
- Sykdommer i det endokrine systemet
- Postoperative komplikasjoner
- Patologiske prosesser
- Genitale neoplasmer, hanner
- Urogenitale neoplasmer
- Neoplasmer etter nettsted
- Neoplasmer
- Kjønnssykdommer, mannlige
- Mannlige urogenitale sykdommer
- Neoplasmer etter histologisk type
- Neoplasmer i endokrine kjertel
- Gonadal lidelser
- Testikkelsykdommer
- Patologiske tilstander, tegn og symptomer
- Tegn og symptomer
- Smerter, postoperativt
- Neoplasmer, kjønnsceller og embryonale
- Testikkelneoplasmer
Andre studie-ID-numre
- 5250002
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .